课题基金 / 基金详情

Osteoporosis Screen for Praja1 E3 Ligase Inhibitors

Osteoporosis Screen for Praja1 E3 Ligase Inhibitors
Praja1 E3 连接酶抑制剂的骨质疏松症筛查
批准号:
7420981
负责人:
Michael R Mattern
金额:
$41.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-06-01 至 2010-04-30

项目摘要

项目成果

Michael R Mattern的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Osteoporosis remains a major challenge to the maintenance of health and quality of life in an aging population. Among the most promising and least exploited therapeutic interventions are those treatments designed to increase bone density. The selection and validation of targets that can be manipulated to achieve this anabolic effect depends on an increasing amount of information relating to bone formation. Progenra has completed the construction and validation for high throughput screening of an assay for Praja1, an E3 ligase responsible for proteasomal degradation of Dlxin-1/MAGE-D1, a coactivator of the transcriptional activator Dlx5. Dlx5 is associated with programmed bone formation. Thus, selective inhibitors of this E3 ligase are hypothesized to increase bone density. Collections of small molecules, as well as plant and marine organism extracts from the NCI, will be screened to find potent and selective inhibitors of Praja1 activity. Lead compounds will be identified from among the hits, and fractionation of active extracts will be guided by the assay, to identify active principles. Among the novel pure compounds arising from this effort, the best will be chosen for evaluation in cultured cell assays for their effects on Praja1-related inhibition of transcription associated with bone formation. Compounds that pass screening and secondary assay evaluation will be considered for animal model evaluation after Phase II. Osteoporosis remains a major challenge to the maintenance of health and quality of life in an aging population; the most sought after treatments are those which will build up bone mass instead of merely preventing further bone loss. Progenra has developed a technology that will permit the discovery of compounds that can work in this fashion; the company proposed to look for new osteoporosis drugs in collections of pure compounds and natural products extracts from plants and marine organisms. The latter have been good sources of highly effective drugs in the past (taxol, statins, etc).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Screen for MURF-1 inhibitors to treat myopathy
  • 批准号:
    7809195
  • 项目类别:
  • 资助金额:
    $28.4万
  • 财政年份:
    2009
  • 负责人:
    Michael R Mattern
  • 依托单位:
Biochemical screen for protein ligation
  • 批准号:
    7271822
  • 项目类别:
  • 资助金额:
    $25.31万
  • 财政年份:
    2007
  • 负责人:
    Michael R Mattern
  • 依托单位:
Ubiquitin E3 ligases and apoptosis in cancer drug discovery
  • 批准号:
    7073879
  • 项目类别:
  • 资助金额:
    $21.41万
  • 财政年份:
    2006
  • 负责人:
    Michael R Mattern
  • 依托单位:
Atrogin-1 inhibitors for Muscle Wasting
  • 批准号:
    7107637
  • 项目类别:
  • 资助金额:
    $24.91万
  • 财政年份:
    2006
  • 负责人:
    Michael R Mattern
  • 依托单位:
海外基金